Listed

Emergent BioSolutions Inc.

EBSNYSECIK 1367644HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$234.3mRevenue, Q2 FY2026, three months to 2026-06-30$234.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$234.3mRevenue, Q2 FY2026, three months to 2026-06-30$234.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure+66.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−53.4%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$125.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $234.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure−54.5 pts on a year earlier
  • Net margin−76.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$180.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $234.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure−68.4 pts on a year earlier
  • Diluted EPS−$3.49Diluted EPS, Q2 FY2026, three months to 2026-06-30−$3.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure−1486.4% on a year earlier
  • Free cash flow$54.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $56.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001367644-26-000082. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001367644-26-000082. Derived: 6-month figure less the 3-month figure.Report this figure−47.8% on a year earlier

Last eight quarters

Full statements
Revenue$234.3mGross margin not reported
Diluted EPS−$3.49, Q2 FY2026
Free cash flow$54.0m, Q2 FY2026
Emergent BioSolutions Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m294Revenue, Q3 FY2024, three months to 2024-09-30$293.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figure195Revenue, Q4 FY2024, three months to 2024-12-31$194.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure222Revenue, Q1 FY2025, three months to 2025-03-31$222.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure141Revenue, Q2 FY2025, three months to 2025-06-30$140.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure231Revenue, Q3 FY2025, three months to 2025-09-30$231.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figure149Revenue, Q4 FY2025, three months to 2025-12-31$148.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure156Revenue, Q1 FY2026, three months to 2026-03-31$156.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure234Revenue, Q2 FY2026, three months to 2026-06-30$234.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure
Gross margin%54.9%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $161.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2024-11-07, accession 0001367644-24-000178.Revenue: $293.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figurenot reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%22.0%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $64.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Revenue: $293.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figure(4.9%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$9.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $194.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure22.5%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $49.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Revenue: $222.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure1.1%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $140.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure33.1%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $76.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Revenue: $231.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figure(18.8%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$27.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $148.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure6.7%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $10.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Revenue: $156.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure(53.4%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$125.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $234.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure
Net margin%39.1%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $114.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Revenue: $293.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figure(16.1%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$31.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $194.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure30.6%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $68.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $222.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure(8.5%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$12.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $140.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure22.2%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $51.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Revenue: $231.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figure(36.7%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$54.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $148.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure4.4%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $6.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $156.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure(76.9%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$180.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Revenue: $234.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure
Diluted EPS$ per share2.06Diluted EPS, Q3 FY2024, three months to 2024-09-30$2.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figurenot reported (Diluted EPS not reported)1.19Diluted EPS, Q1 FY2025, three months to 2025-03-31$1.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure(0.22)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure0.91Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001367644-25-000202.Report this figurenot reported (Diluted EPS not reported)0.07Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure(3.49)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$3.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001367644-26-000082.Report this figure
Free cash flow$m148Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $153.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001367644-25-000202. Derived: 9-month figure less the 6-month figure.Capital expenditure: $5.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001367644-25-000202. Derived: 9-month figure less the 6-month figure.Report this figure(81.6)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$79.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(14.8)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$11.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Capital expenditure: $3.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure104Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $106.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001367644-26-000082. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001367644-26-000082. Derived: 6-month figure less the 3-month figure.Report this figure(5.7)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$2.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001367644-25-000202. Derived: 9-month figure less the 6-month figure.Capital expenditure: $3.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001367644-25-000202. Derived: 9-month figure less the 6-month figure.Report this figure73.8Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $77.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Capital expenditure: $3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001367644-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure(36.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$33.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0001367644-26-000065.Report this figure54.0Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $56.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001367644-26-000082. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001367644-26-000082. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$742.9mGross margin not reported
Diluted EPS$0.93, FY2025
Free cash flow$156.8m, FY2025
Emergent BioSolutions Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1,774Revenue, FY2021, twelve months to 2021-12-31$1.77bn. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-08, accession 0001367644-24-000033.Report this figure1,118Revenue, FY2022, twelve months to 2022-12-31$1.12bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001367644-25-000021.Report this figure1,049Revenue, FY2023, twelve months to 2023-12-31$1.05bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure1,044Revenue, FY2024, twelve months to 2024-12-31$1.04bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure743Revenue, FY2025, twelve months to 2025-12-31$742.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure
Gross margin%50.3%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $891.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-08, accession 0001367644-24-000033.Revenue: $1.77bn. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-08, accession 0001367644-24-000033.Report this figure34.3%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $383.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-08, accession 0001367644-24-000033.Revenue: $1.12bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001367644-25-000021.Report this figure30.3%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $317.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-08, accession 0001367644-24-000033.Revenue: $1.05bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figurenot reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%19.2%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $341.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-08, accession 0001367644-24-000033.Revenue: $1.77bn. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-08, accession 0001367644-24-000033.Report this figure(15.2%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$170.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-04, accession 0001367644-25-000021.Revenue: $1.12bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001367644-25-000021.Report this figure(69.2%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$726.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015.Revenue: $1.05bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure(10.4%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$108.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015.Revenue: $1.04bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure13.5%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $100.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015.Revenue: $742.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure
Net margin%12.4%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $219.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-08, accession 0001367644-24-000033.Revenue: $1.77bn. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-08, accession 0001367644-24-000033.Report this figure(18.9%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$211.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-04, accession 0001367644-25-000021.Revenue: $1.12bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001367644-25-000021.Report this figure(72.5%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$760.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015.Revenue: $1.05bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure(18.3%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$190.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015.Revenue: $1.04bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure7.1%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $52.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001367644-26-000015.Revenue: $742.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure
Diluted EPS$ per share4.06Diluted EPS, FY2021, twelve months to 2021-12-31$4.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-08, accession 0001367644-24-000033.Report this figure(4.22)Diluted EPS, FY2022, twelve months to 2022-12-31−$4.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-04, accession 0001367644-25-000021.Report this figure(14.85)Diluted EPS, FY2023, twelve months to 2023-12-31−$14.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure(3.60)Diluted EPS, FY2024, twelve months to 2024-12-31−$3.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure0.93Diluted EPS, FY2025, twelve months to 2025-12-31$0.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure
Free cash flow$m96.1Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $320.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-08, accession 0001367644-24-000033.Capital expenditure: $224.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-08, accession 0001367644-24-000033.Report this figure(150)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$34.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-04, accession 0001367644-25-000021.Capital expenditure: $115.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-04, accession 0001367644-25-000021.Report this figure(258)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$206.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001367644-26-000015.Capital expenditure: $51.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure35.8Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $58.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001367644-26-000015.Capital expenditure: $22.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure157Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $170.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001367644-26-000015.Capital expenditure: $13.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001367644-26-000015.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Emergent BioSolutions Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$39.5m4,716,599Added+375,137
DIMENSIONAL FUND ADVISORS LP2026-06-30$25.8m3,076,646Added+319,488
STATE STREET CORP2026-06-30$24.6m2,929,238Added+79,537
AMERICAN CENTURY COMPANIES INC2026-06-30$23.2m2,770,448Added+344,726
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$18.4m2,198,839Reduced−59,156
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$11.2m1,337,243Added+64,334
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2026-06-30$10.1m1,200,791Reduced−305,284
OAK HILL ADVISORS LP2026-06-30$9.3m1,113,338Unchanged
MILLENNIUM MANAGEMENT LLC2026-06-30$9.0m1,072,185Added+540,184
Ancora Advisors LLC2026-06-30$8.9m1,067,867Added+658,600

Recent filings

All 1,415 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Emergent BioSolutions Inc., recent filings
FiledFormWhat it isAccession number
2026-10-1611:48 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001367644-26-000098
2026-09-1420:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001367644-26-000091
2026-09-0120:13 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001367644-26-000088
2026-08-0621:47 ET10-QQuarterly reportPeriod 2026-06-300001367644-26-000082
2026-08-0520:06 ET8-K2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001367644-26-000080
2026-06-2915:14 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001367644-26-000068
2026-05-0121:54 ET10-QQuarterly reportPeriod 2026-03-310001367644-26-000065
2026-04-3020:32 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001367644-26-000059
2026-04-3011:30 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001367644-26-000051
2026-04-1721:51 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001367644-26-000038

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1367644
Tickers
EBS
Exchange
NYSE
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. Listed shows no prices and gives no investment advice.